[go: up one dir, main page]

Dai et al., 2017 - Google Patents

Mussel-inspired polydopamine-coated lanthanide nanoparticles for NIR-II/CT dual imaging and photothermal therapy

Dai et al., 2017

Document ID
9671013738191135597
Author
Dai Y
Yang D
Yu D
Cao C
Wang Q
Xie S
Shen L
Feng W
Li F
Publication year
Publication venue
ACS applied materials & interfaces

External Links

Snippet

Nanomedicine has attracted substantial attention for the accurate diagnosis or treatment of carcinoma in recent years. Nd3+-doped lanthanide nanophosphor-based near-infrared-II (NIR-II) optical imaging is widely used for deep penetration tissue imaging while X-ray …
Continue reading at pubs.acs.org (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
    • A61K47/48853—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere
    • A61K47/48861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere the form being an inorganic particle, e.g. a ceramic particle, silica particle, ferrite, synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer

Similar Documents

Publication Publication Date Title
Dai et al. Mussel-inspired polydopamine-coated lanthanide nanoparticles for NIR-II/CT dual imaging and photothermal therapy
Lv et al. In situ growth strategy to integrate up-conversion nanoparticles with ultrasmall CuS for photothermal theranostics
Zhao et al. Near-infrared light-triggered lysosome-targetable carbon dots for photothermal therapy of cancer
Bi et al. Bismuth nanoparticles with “light” property served as a multifunctional probe for X-ray computed tomography and fluorescence imaging
Meng et al. Accurate and real-time temperature monitoring during MR imaging guided PTT
Xu et al. All-in-one theranostic nanomedicine with ultrabright second near-infrared emission for tumor-modulated bioimaging and chemodynamic/photodynamic therapy
Mauro et al. Functionalization of metal and carbon nanoparticles with potential in cancer theranostics
Li et al. Theranostic carbon dots with innovative NIR-II emission for in vivo renal-excreted optical imaging and photothermal therapy
Lei et al. Yb3+/Er3+-codoped Bi2O3 nanospheres: probe for upconversion luminescence imaging and binary contrast agent for computed tomography imaging
Dong et al. Multimode imaging-guided photothermal/chemodynamic synergistic therapy nanoagent with a tumor microenvironment responded effect
Ding et al. Multifunctional core/satellite polydopamine@ Nd3+-sensitized upconversion nanocomposite: A single 808 nm near-infrared light-triggered theranostic platform for in vivo imaging-guided photothermal therapy
Yang et al. Nanoscale metal–organic particles with rapid clearance for magnetic resonance imaging-guided photothermal therapy
Yang et al. A-DA′ DA structured organic phototheranostics for NIR-II fluorescence/photoacoustic imaging-guided photothermal and photodynamic synergistic therapy
Feng et al. Controllable generation of free radicals from multifunctional heat-responsive nanoplatform for targeted cancer therapy
Ma et al. Enhanced radiosensitization of gold nanospikes via hyperthermia in combined cancer radiation and photothermal therapy
Lei et al. Optimization of Bi3+ in upconversion nanoparticles induced simultaneous enhancement of near-infrared optical and X-ray computed tomography imaging capability
Kong et al. A general strategy for ligand exchange on upconversion nanoparticles
Wang et al. A dual-targeting upconversion nanoplatform for two-color fluorescence imaging-guided photodynamic therapy
Yang et al. Recent progress on second near-infrared emitting carbon dots in biomedicine
Tian et al. Sub-10 nm Fe3O4@ Cu2–x S core–shell nanoparticles for dual-modal imaging and photothermal therapy
Zou et al. Design and synthesis of a lead sulfide based nanotheranostic agent for computer tomography/magnetic resonance dual-mode-bioimaging-guided photothermal therapy
Ma et al. NaGdF4: Yb3+/Er3+@ NaGdF4: Nd3+@ sodium-gluconate: multifunctional and biocompatible ultrasmall core–shell nanohybrids for UCL/MR/CT multimodal imaging
Zhang et al. Multifunctional core− shell nanoparticles as highly efficient imaging and photosensitizing agents
Wang et al. AIEgen-based polymer nanocomposites for imaging-guided photothermal therapy
Gulzar et al. An 808 nm light-sensitized upconversion nanoplatform for multimodal imaging and efficient cancer therapy